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Abstract 
Purpose: To investigate the effect of withaferin A on the suppression of the anti-apoptotic genes, BCL2, 
Bcl-xL, XIAP and Survivin), in cervical carcinoma cells. 
Methods: Annexin V-FITC/propidium iodide (PI) staining was used for the investigation of cell 
apoptosis. RNA RNeasy Kits was used to isolate RNA and Omniscript RT to reverse and transcribe the 
mRNA. Quantitative real-time polymerase chain reaction (qPCR) was performed using Taq PCR Master 
Mix Kit. 
Results: Withaferin A (WFA) treatment reduced mRNA and protein levels of antiapoptotic genes in 
MCF-7 and HeLa cervical carcinoma cells. Suppression of BCL2, Bcl-xL, XIAP and Survivin induced a 
significant anti-proliferative effect. Treatment with WFA at a concentration of 20 μM, decreased cell 
viability and induced apoptosis. In MCF-7 cells, knockdown of BCL2, Bcl-xL, XIAP and Survivin caused 
4-fold enhancement in apoptosis rate and 53 % decrease in cell viability.  
Conclusion: WFA significantly leads to knockdown of antiapoptotic genes and is, therefore, a 
promising treatment strategy for cervical cancer. 
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Cervical cancer is the most frequently observed 
cancer in women throughout the world. It is 
estimated that every year 500,000 new cervical 
carcinoma cases are detected globally and 80 % 
of them are from developing countries [1,2]. 
Currently, surgery, radiation and chemotherapy 
are used for the treatment of cervical cancer. 
Intracavitary brachytherapy is a technique used 
to deliver high radiation doses to tumor site 
without exposing normal tissues to radiation [3,]. 
Presently, the combination of external beam 
radiotherapy and intracavitary brachytherapy is 
considered to be the standard treatment strategy 
for cervical cancer. Although high cure rates are 
reported at the early stage of the disease using 
definitive radiotherapy, in locally advanced 
cervical cancer cases the cure rates are poor. 
The 5-year overall survival of only 66 % are 
reported at the advanced stages [5]. Thus, the 
discovery of molecules with roles in the treatment 
of locally advanced cervical cancer is needed. 
 
Maintenance of homeostasis in normal tissues 
and selective removal of damaged and infected 
cells is achieved by the process of apoptosis 
[6].Tumor cells are bestowed with the ability to 
escape apoptosis [7]. It is reported that tumor 
cells express higher concentration of 
antiapoptotic genes including BCL2, Bcl-xL, XIAP 
and Survivin which enables them to evade 
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apoptosis. Among the antiapoptotic genes, BCL2 
and Bcl-xL help to escape apoptosis by inhibiting 
cytochrome release from the mitochondria 
followed by failure to activate caspases [8]. 
Caspases on activation induce apoptosis in 
which proteins essential for cell function and 
stability are cleaved [9].  
 
Extracts of withaferin A isolate from Witha 
niasomnifera, are used in traditional East Indian 
medicine [10]. Withaferin A is the major 
compound present in the extract of Witha 
niasomnifera [11,12]. Withaferin A has anti-
angiogenic effects [10,13] from micromolar doses 
and inhibits soft tissue sarcoma growth and local 
recurrence in xenograft experiments [14]. It 
exhibits proapoptotic and anti-tumor activitities in 
breast and prostate cancers [15–17]. It is 
reported that withaferin A usually exerts its effect 
through NF-Kb, BCL-2, FOXO3A, Hsp90, 
phosphorylated STAT3 and annexin II [16,18–
22]. In the present study, effect of WFA on 
knockdown of antiapoptotic genes including 
BCL2, Bcl-xL, XIAP and Survivin human cervical 




Cell lines and cell culture  
 
The human cervical carcinoma cell lines MCF-7, 
HeLa and ME-180 were purchased from 
American Type of Culture Collection (ATCC, 
Manassas, VA, USA). The cells were cultured 
under standard conditions at 37 oC in humidified 
atmosphere containing 5 % CO2. 
 
Reagents and chemicals 
 
Withaferin A (WFA) was purchased from Sigma 
Aldrich (St. Louis, MO, USA) and dissolved in 
dimethyl sulfoxide (DMSO) to a concentration of 
100 µM as a stock solution. Rabbit antihuman 
Caspase-3, mouse antihuman Bcl-2, and β-actin 
were purchased from Cell Signaling (China). 
 
Cell viability assay 
 
Cervical carcinoma cells were incubated with 
various concentrations of WFA at 37 oC for 72 h. 
MTT viability assay was performed according to 
manual protocol (Roche Diagnostics). The 





Annexin V-FITC/propidium iodide (PI) staining 
(Annexin V-FITC Apoptosis Detection Kit I, BD 
Biosciences, Heidelberg, Germany) was used to 
examine the apoptosis in cervical carcinoma 
cells. After 48 h of WFA treatment flow, 
cytometry (FACScan, BD Biosciences) was used 
to examine the cells. The quadrant analysis of 
Annexin V-FITC/PI plots was performed to 
determine the percentage of early (Annexin V-
FITC positive, PI negative) and late (Annexin V-
FITC positive, PI positive) apoptotic cells. For 
this purpose, WinMDI2.8 software was 
employed.  
 
Reverse transcriptase PCR 
 
For the isolation of total cell RNA RNeasy Kits 
(Qiagen) was used. The RNA sample (500 ng) 
was used for reverse transcription to cDNA using 
Omniscript RT (Qiagen). The cDNA was then 
employed for quantitative real-time PCR (qPCR) 
using Taq PCR Master Mix Kit (Qiagen) 
according to the manual protocol. 
 
Western blot analysis 
 
The cells after WFA treatment were lysed in ice 
cold lysis buffer supplemented with protease 
inhibitors. The cell lysate was subjected to SDS-
PAGE separation. Proteins were transferred to 
polyvinyl idenedi fluoride (PVDF) membrane (GE 
Healthcare, Freiburg, Germany) and then 
incubated with the primary antibodies. The 
antibodies were used against BCL2, Bcl-xL, 
XIAP and Survivin (Sigma-Aldrich, St. Louis, MO, 
USA) and anti-β-actin was used as the loading 
control (Sigma-Aldrich, St. Louis, MO, USA). The 
polyclonal anti-rabbit immunoglobulin HRP-linked 
antibody and polyclonal rabbit anti-mouse 
immunoglobulin HRP-linked antibody were used 
as the secondary antibodies. For visualization, 





Antiapoptotic gene expression in MCF-7, 
HeLa and ME-180 cervical carcinoma cell 
lines 
 
The expression levels of the four antiapoptotic 
genes in MCF-7, HeLa and ME-180 cervical 
cancer cells was analyzed by quantitative PCR 
analysis. In all the tested cervical carcinoma cell 
lines, BCL2, Bcl-xL, XIAP and Survivin were 
expressed at higher level (Table 1). Among the 
three tested cell lines, MCF-7 and HeLa cells 
expressed all the four genes which are 
antiapoptotic at significantly higher levels thus, 
were selected for further studies. 
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Table 1: Expression levels of mRNA in MCF-7, HeLa 




BCL2 Bcl-xL XIAP Survivin 
MCF-7 0.411 33.6 4.38 5.76 
HeLa 0.134 31.3 3.12 3.87 
ME-180 0.132 11.2 2.64 2.59 
 
Effect of WFA on expression of genes 
involved in anti-apoptosis 
 
Among the range of WFA concentrations from 5 
to 50 μM used to analyse the effect on 
antiapoptotic gene inhibition, the effect was 
significant at 30 μM concentration. Although, 20 
μM WFA concentrations markedly reduced the 
mRNA levels by 52-59 % after 24 h treatment, 
the inhibition rate was increased to 81– 86 % at 
30 μM concentration of WFA (Figure 1). Thus, a 
marked antiapoptotic gene inhibition was 
observed after WFA treatment in MCF-7 and 
HeLa cell lines. 
 
Molecular effects of WFA on inhibition of 
genes involved in antiapoptosis  
 
WFA at 30 μM concentration significantly 
inhibited the mRNA expression levels of 
antiapoptotic genes in the cervical carcinoma cell 
lines after 48 h treatment (Figure 2). BCL2, Bcl-
xL, XIAP and Survivin were decreased 
respectively by 32 39 42 and 36 % in MCF-7 
cells. The results from western blot analysis 
showed protein reduction after 48 h of WFA 
treatment in both MCF-7 and HeLa cervical 






Figure 1: Decrease in the level of BCL2, Bcl-xL, XIAP and Survivin mRNA on treatment with WFA for 24 h in 
MCF-7 (upper figure) and HeLa (lower figure) cervical cell lines 
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Figure 2: Relative mRNA expression levels of MCF-7 and HeLa cervical carcinoma cells 48 h after treatment 




Figure 3: Western blot used to detect BCL2, Bcl-xL, XIAP and Survivin protein in MCF-7 and HeLa cervical 
carcinoma cells after 48 h of WFA treatment 
 
Cellular effects of WFA treatment 
 
The WFA-mediated inhibition of anti-apoptotic 
genes led to a significant decrease in cervical 
cancer cell viability (Figure4). The cervical 
carcinoma cell viability was decreased by 39 and 
46 % in MCF-7 and HeLa cells respectively after 
treatment with WFA for 96 h. The rate of cell 
apoptosis was also significantly increased on 
treatment with WFA. In MCF-7cells, there was a 
4-fold increase in the rate of apoptosis (Figure 5). 
In HeLa cells apoptosis was increased by 3.5 
fold (Figure 5). However, no changes were 
observed in the cell cycle distribution in MCF-7 
and HeLa cells on treatment with WFA. 
   
Figure 4: Viability of MCF-7 and HeLa cervical 
carcinoma cells 96 h after WFA treatment  
 
Ye & Song 




Figure 5: Percentage of early and late apoptotic cells 
48 h after WFA treatment of MCF-7 and HeLa cells. 





In tumor tissues the expression of various 
antiapoptotic genes is found to be markedly 
higher and plays an important role in inhibiting 
the induction of apoptosis [23-25]. Thus, 
antiapoptotic gene inhibition can be a potent 
strategy for antitumor therapy. It is believed that 
the inhibition of one antiapoptotic gene can be 
compensated by the expression of other genes, 
therefore, inhibition of all the major antiapoptotic 
genes can have the greatest effect. In the 
present study, treatment of MCF-7 and HeLa 
cervical carcinoma cells with 30 μM of WFA 
resulted in the suppression of mRNA 
corresponding to antiapoptotic gene. WFA 
significantly inhibited the mRNA and protein 
levels of anti-apoptotic genes and exhibited 
strong anti-proliferative effects on MCF-7 and 
HeLa cervical carcinoma cells. In MCF-7 and 
HeLa cervical carcinoma cells the proliferation 
was reduced by 39 and 46 %, respectively 
following WFA treatment for 96 h. Tumor cells 
are bestowed with the ability to avoid the process 
of apoptosis [7]. It is reported that the tumor cells 
express higher level of BCL2, Bcl-xL, XIAP and 
Survivin antiapoptotic genes which enables them 
to evade apoptosis. The rate of cell apoptosis 
was also significantly increased on treatment 
with WFA. In MCF-7 cells, there was a 4-fold 
increase in the rate of apoptosis. In case of the 
HeLa cells the proportion of apoptotic cells was 
enhanced by 3.5 fold on treatment with WFA. 
However, in both MCF-7 and HeLa cells WFA 
treatment could not induce any alteration in the 
progression of cell cycle. Thus, the current study 
demonstrates that WFA induces suppression of 
antiapoptotic gene expression which can be a 





Thus withaferin A significantly inhibits cervical 
cancer via knockdown of antiapoptotic genes and 
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